The McKesson-backed healthcare analytics software provider boosted its valuation to $3.3bn in a series E round that came just two months after its series D.

Novo and Lundbeck are in line for exits from the mitochondrial disease therapy developer, which has raised $145m across two funding rounds.

Lilly Asia Ventures co-led a $61.4m round for the antibody drug developer that will fund development of breast and gastric cancer drug candidates.

Peking University-backed Yanchuang Capital co-led a series A round for Innoforce Pharmaceuticals that will support the construction of manufacturing facilities.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

University of Colorado Innovation Fund has participated in a funding round for Riva Health that also attracted its affiliate health system UCHealth.

Eli Lilly has scored an exit after the inflammatory disease drug developer, which is now valued at about $1bn, went public.

SymBiosis and SIG-backed microbiome therapeutics developer Finch priced an upsized offering at the top of its range.

Cash Capital has participated in a $70m series B round for Shanghai ZhenGe Biotechnology, bringing the company’s total financing to $125m.

UCHealth contributed to a $15.5m round for the cardiovascular data platform developer that was led by Menlo Ventures.